Trial of INI-4001 in Patients With Advanced Solid Tumours
Status:
RECRUITING
Trial end date:
2027-03-30
Target enrollment:
Participant gender:
Summary
Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.